Results 1 to 10 of about 141,302 (117)

CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges

Frontiers in Immunology, 2022
Chimeric antigen receptor T (CAR-T) cell therapy represents a major breakthrough in cancer treatment, and it has achieved unprecedented success in hematological malignancies, especially in relapsed/refractory (R/R) B cell malignancies.
Lingling Zhu, Shanshan Chen
exaly   +3 more sources

Impact of Manufacturing Procedures on CAR T Cell Functionality

Frontiers in Immunology, 2022
The field of chimeric antigen receptor (CAR) modified T cell therapy has rapidly expanded in the past few decades. As of today, there are six CAR T cell products that have been approved by the FDA: KYMRIAH (tisagenlecleucel, CD19 CAR T cells), YESCARTA ...
Norihiro Watanabe, Feiyan Mo
exaly   +3 more sources

Preventing trogocytosis by cathepsin B inhibition augments CAR T-cell function. [PDF]

Signal Transduct Target Ther
Chimeric antigen receptor (CAR) T-cell therapy has shown remarkable efficacy in cancer treatment. Nevertheless, most patients receiving CAR T cells relapse within 5 years of treatment. CAR-mediated trogocytosis (CMT) is a potential tumor escape mechanism
Dietze KA, Nguyen K, Pathni A, Fazekas F, Sun W, Rosati E, Baker JM, Galeana Figueroa M, Gebru E, Yamoah D, Mulatu R, Wang A, Rapoport AP, Lum DH, Fan X, Radhakrishnan SV, Atanackovic D, Upadhyaya A, Luetkens T.   +18 more
europepmc   +2 more sources

Nanoscale CAR Organization at the Immune Synapse Correlates with CAR-T Effector Functions

Cells, 2023
T cells expressing chimeric antigen receptors (CARs) are at the forefront of clinical treatment of cancers. Still, the nanoscale organization of CARs at the interface of CAR-Ts with target cells, which is essential for TCR-mediated T cell activation ...
Julia Sajman, Oren Yakovian, Naamit Unger Deshet, Shaked Almog, Galit Horn, Tova Waks, Anat Globerson Levin, Eilon Sherman   +7 more
doaj   +1 more source

Search, identification, and curation of cell and gene therapy product regulations using augmented intelligent systems

Frontiers in Medicine, 2023
BackgroundManually keeping up-to-date with regulations such as directives, guidance, laws, and ordinances related to cell and gene therapy is a labor-intensive process. We used machine learning (ML) algorithms to create an augmented intelligent system to
William Schaut, Akash Shrivastav, Srikanth Ramakrishnan, Robert Bowden   +3 more
doaj   +1 more source

Monitoring of Circulating CAR T Cells: Validation of a Flow Cytometric Assay, Cellular Kinetics, and Phenotype Analysis Following Tisagenlecleucel

Frontiers in Immunology, 2022
Chimeric antigen receptor (CAR) T cell therapy is a potent new treatment option for relapsed or refractory hematologic malignancies. As the monitoring of CAR T cell kinetics can provide insights into the activity of the therapy, appropriate CAR T cell ...
Andreas Peinelt, Andreas Peinelt, Melanie Bremm, Melanie Bremm, Hermann Kreyenberg, Hermann Kreyenberg, Claudia Cappel, Claudia Cappel, Julia Banisharif-Dehkordi, Julia Banisharif-Dehkordi, Stephanie Erben, Stephanie Erben, Eva Rettinger, Eva Rettinger, Andrea Jarisch, Andrea Jarisch, Roland Meisel, Paul-Gerhardt Schlegel, Olaf Beck, Gesine Bug, Jan-Henning Klusmann, Thomas Klingebiel, Sabine Huenecke, Sabine Huenecke, Peter Bader, Peter Bader   +25 more
doaj   +1 more source

CAR T cell therapy

Immunological Medicine, 2021
Chimeric antigen receptor (CAR) is generated by fusing a cancer-specific antibody’s antigen recognition site with costimulatory molecules such as CD28 and CD3ζ. T cells transduced with CAR recognizes cancer-specific antigens and kill cancer cells.
Naoki Hosen
doaj   +1 more source

Novel adapter CAR-T cell technology for precisely controllable multiplex cancer targeting

OncoImmunology, 2021
Chimeric antigen receptor (CAR)-T therapy holds great promise to sustainably improve cancer treatment. However, currently, a broad applicability of CAR-T cell therapies is hampered by limited CAR-T cell versatility and tractability and the lack of ...
Christian M. Seitz, Joerg Mittelstaet, Daniel Atar, Jana Hau, Selina Reiter, Clara Illi, Verena Kieble, Fabian Engert, Britta Drees, Giulia Bender, Ann-Christin Krahl, Philipp Knopf, Sarah Schroeder, Nikolas Paulsen, Alexander Rokhvarguer, Sophia Scheuermann, Elena Rapp, Anna-Sophia Mast, Armin Rabsteyn, Sabine Schleicher, Stefan Grote, Karin Schilbach, Manfred Kneilling, Bernd Pichler, Dominik Lock, Bettina Kotter, Sandra Dapa, Stefan Miltenyi, Andrew Kaiser, Peter Lang, Rupert Handgretinger, Patrick Schlegel   +31 more
doaj   +1 more source

CAR T cell therapy becomes CHIC: “cytokine help intensified CAR” T cells

Frontiers in Immunology, 2023
Chimeric antigen receptors (CARs) in the canonical “second generation” format provide two signals for inducing T cell effector functions; the primary “signal-1” is provided through the TCR CD3ζ chain and the “signal-2” through a linked costimulatory ...
Simone Thomas, Simone Thomas, Hinrich Abken, Hinrich Abken   +3 more
doaj   +1 more source

Transgenic expression of IL-7 regulates CAR-T cell metabolism and enhances in vivo persistence against tumor cells

Scientific Reports, 2022
Chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising novel therapeutic approach. However, primary and secondary resistance to CAR-T cell therapy is commonly encountered in various clinical trials. Despite the comprehensive studies to
Li Li, Qing Li, Zi-Xun Yan, Ling-Shuang Sheng, Di Fu, Pengpeng Xu, Li Wang, Wei-Li Zhao   +7 more
doaj   +1 more source